Kevin Gordon Sells 5,500 Shares of Progyny (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) Director Kevin Gordon sold 5,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $24.99, for a total transaction of $137,445.00. Following the transaction, the director owned 9,318 shares in the company, valued at approximately $232,856.82. This trade represents a 37.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Progyny Trading Down 0.5%

Shares of PGNY opened at $25.56 on Friday. The firm has a market cap of $2.00 billion, a PE ratio of 33.19, a price-to-earnings-growth ratio of 1.36 and a beta of 0.91. The company’s 50 day simple moving average is $19.83 and its 200-day simple moving average is $22.25. Progyny, Inc. has a 12-month low of $16.10 and a 12-month high of $28.75.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.24. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.47 million. During the same period last year, the firm posted $0.17 EPS. Progyny’s quarterly revenue was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, equities research analysts forecast that Progyny, Inc. will post 1.12 EPS for the current fiscal year.

Progyny declared that its board has authorized a share repurchase plan on Tuesday, May 26th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 10.3% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd acquired a new position in shares of Progyny during the 4th quarter valued at about $25,000. Federated Hermes Inc. grew its holdings in shares of Progyny by 147.3% during the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock worth $30,000 after purchasing an additional 819 shares during the period. Hantz Financial Services Inc. grew its holdings in shares of Progyny by 79.4% during the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after purchasing an additional 742 shares during the period. Quarry LP grew its holdings in shares of Progyny by 2,004.1% during the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after purchasing an additional 3,427 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Progyny during the 2nd quarter worth about $77,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on PGNY shares. KeyCorp reduced their target price on Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. Truist Financial raised their target price on Progyny from $28.00 to $30.00 and gave the company a “buy” rating in a report on Monday, May 11th. Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Citigroup reissued an “outperform” rating on shares of Progyny in a report on Monday, May 11th. Finally, Citizens Jmp raised their target price on Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, Progyny presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.55.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.